NO2020035I1 - cefiderokol, eventuelt på formen av et farmasøytisk akseptabelt salt eller solvat - Google Patents
cefiderokol, eventuelt på formen av et farmasøytisk akseptabelt salt eller solvatInfo
- Publication number
- NO2020035I1 NO2020035I1 NO2020035C NO2020035C NO2020035I1 NO 2020035 I1 NO2020035 I1 NO 2020035I1 NO 2020035 C NO2020035 C NO 2020035C NO 2020035 C NO2020035 C NO 2020035C NO 2020035 I1 NO2020035 I1 NO 2020035I1
- Authority
- NO
- Norway
- Prior art keywords
- cefiderocol
- solvate
- optionally
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- DBPPRLRVDVJOCL-FQRUVTKNSA-N cefiderocol Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1(CCNC(=O)C=2C(=C(O)C(O)=CC=2)Cl)CCCC1 DBPPRLRVDVJOCL-FQRUVTKNSA-N 0.000 title 1
- 229950000788 cefiderocol Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 239000012453 solvate Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
- C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D505/10—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D505/12—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7
- C07D505/14—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7 with hetero atoms directly attached in position 7
- C07D505/16—Nitrogen atoms
- C07D505/18—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof
- C07D505/20—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D505/24—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen further substituted by doubly-bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/06—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 containing at least one condensed beta-lactam ring system, provided for by groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00, e.g. a penem or a cepham system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008280828 | 2008-10-31 | ||
| EP09823578.1A EP2341053B1 (en) | 2008-10-31 | 2009-10-27 | Cephalosporin having catechol group |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2020035I1 true NO2020035I1 (no) | 2020-10-21 |
Family
ID=42128829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO2020035C NO2020035I1 (no) | 2008-10-31 | 2020-10-21 | cefiderokol, eventuelt på formen av et farmasøytisk akseptabelt salt eller solvat |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US9238657B2 (no) |
| EP (2) | EP2341053B1 (no) |
| JP (2) | JP5498393B2 (no) |
| KR (1) | KR101655961B1 (no) |
| CN (1) | CN102203100B (no) |
| AU (1) | AU2009310959B2 (no) |
| BR (1) | BRPI0921701B8 (no) |
| CA (1) | CA2736953C (no) |
| CL (1) | CL2011000939A1 (no) |
| CO (1) | CO6331443A2 (no) |
| CR (1) | CR20110144A (no) |
| CY (2) | CY1118536T1 (no) |
| DK (1) | DK2960244T3 (no) |
| EA (1) | EA019520B1 (no) |
| ES (2) | ES2602969T3 (no) |
| FI (1) | FIC20200039I1 (no) |
| FR (1) | FR20C1050I2 (no) |
| HR (1) | HRP20161408T1 (no) |
| HU (2) | HUE031802T2 (no) |
| IL (1) | IL211720A (no) |
| LT (2) | LT2960244T (no) |
| MA (1) | MA32731B1 (no) |
| ME (1) | ME02666B (no) |
| MX (1) | MX2011004636A (no) |
| MY (1) | MY155655A (no) |
| NL (1) | NL301067I2 (no) |
| NO (1) | NO2020035I1 (no) |
| NZ (1) | NZ591728A (no) |
| PE (1) | PE20120010A1 (no) |
| PL (1) | PL2960244T3 (no) |
| PT (1) | PT2960244T (no) |
| RS (1) | RS55365B1 (no) |
| SI (1) | SI2960244T1 (no) |
| SM (1) | SMT201600397B (no) |
| TW (1) | TWI535727B (no) |
| UA (1) | UA105190C2 (no) |
| WO (1) | WO2010050468A1 (no) |
| ZA (1) | ZA201102024B (no) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009049086A1 (en) | 2007-10-09 | 2009-04-16 | Larry Sutton | Broad spectrum beta-lactamase inhibitors |
| AU2009310959B2 (en) | 2008-10-31 | 2015-05-07 | Shionogi & Co., Ltd. | Cephalosporin having catechol group |
| MX2012011521A (es) | 2010-04-05 | 2013-03-08 | Shionogi & Co | Compuestos cefem que tienen un grupo catecol. |
| US8883773B2 (en) | 2010-04-05 | 2014-11-11 | Shionogi & Co., Ltd. | Cephem compound having pseudo-catechol group |
| WO2011136268A1 (ja) * | 2010-04-28 | 2011-11-03 | 塩野義製薬株式会社 | 新規なセフェム誘導体 |
| WO2012121973A1 (en) | 2011-03-04 | 2012-09-13 | Life Technologies Corporation | Compounds and methods for conjugation of biomolecules |
| KR101719556B1 (ko) * | 2011-03-30 | 2017-03-24 | 주식회사 레고켐 바이오사이언스 | 신규한 세파로스포린 유도체 및 이를 함유하는 의약 조성물 |
| CA2833121A1 (en) | 2011-04-28 | 2012-11-01 | Shionogi & Co., Ltd. | Novel cephem compound having catechol or pseudo-catechol structure |
| WO2013002215A1 (ja) | 2011-06-27 | 2013-01-03 | 塩野義製薬株式会社 | ピリジニウム基を有するセフェム化合物 |
| TWI547496B (zh) | 2011-10-04 | 2016-09-01 | 葛蘭素集團公司 | 抗菌化合物 |
| WO2013051597A1 (ja) | 2011-10-04 | 2013-04-11 | 塩野義製薬株式会社 | カテコール基を有するセフェム誘導体 |
| US9527866B2 (en) | 2012-10-29 | 2016-12-27 | Shionogi & Co., Ltd. | Processes for production of intermediates for 2-alkyl cephem compounds |
| UY35103A (es) * | 2012-10-29 | 2014-05-30 | Glaxo Group Ltd | Compuestos de cefem 2-sustituidos |
| WO2014104148A1 (ja) * | 2012-12-26 | 2014-07-03 | 塩野義製薬株式会社 | セフェム化合物 |
| WO2015035376A2 (en) | 2013-09-09 | 2015-03-12 | Calixa Therapeutics, Inc. | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
| PL3122745T3 (pl) | 2014-03-24 | 2019-08-30 | Novartis Ag | Monobaktamowe związki organiczne do leczenia zakażeń bakteryjnych |
| JP6377570B2 (ja) * | 2014-04-28 | 2018-08-22 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | ２−置換セフェム化合物を含有する医薬組成物 |
| KR20220065084A (ko) | 2014-06-11 | 2022-05-19 | 베나토알엑스 파마슈티컬스, 인크. | 베타-락타마제 억제제 |
| CN106661052B (zh) * | 2014-09-04 | 2021-05-11 | 盐野义制药株式会社 | 头孢菌素衍生物的中间体及其制造方法 |
| US10004750B2 (en) * | 2014-09-04 | 2018-06-26 | Shionogi & Co., Ltd. | Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof |
| KR101935186B1 (ko) * | 2014-09-04 | 2019-01-03 | 시오노기세야쿠 가부시키가이샤 | 카테콜기를 갖는 세팔로스포린류를 함유하는 제제 |
| WO2016198691A1 (en) | 2015-06-11 | 2016-12-15 | Basilea Pharmaceutica Ag | Efflux-pump inhibitors and therapeutic uses thereof |
| DK3353175T3 (da) | 2015-09-23 | 2020-09-14 | Novartis Ag | Salte og faste former af et monobactam-antibiotikum |
| US9751894B2 (en) * | 2015-12-10 | 2017-09-05 | Naeja-Rgm Pharmaceuticals Inc. | Cephem compounds, their production and use |
| JP6918819B2 (ja) | 2016-03-08 | 2021-08-11 | ノバルティス アーゲー | オルトミクソウイルス感染の処置に有用な三環式化合物 |
| WO2017216765A1 (en) * | 2016-06-17 | 2017-12-21 | Wockhardt Limited | Antibacterial compositions |
| JOP20170169A1 (ar) | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| EP3630783A4 (en) | 2017-05-26 | 2021-03-03 | Venatorx Pharmaceuticals, Inc. | PENICILLIN BINDING PROTEIN INHIBITORS |
| WO2018227178A1 (en) * | 2017-06-09 | 2018-12-13 | Fob Synthesis, Inc. | Carbapenem compounds and compositions for the treatment of bacterial infections |
| WO2019026004A2 (en) | 2017-08-02 | 2019-02-07 | Novartis Ag | CHEMICAL PROCESS FOR THE PREPARATION OF ANTIBIOTIC MONOBACTAM AND ITS INTERMEDIATES |
| PE20210403A1 (es) | 2018-02-28 | 2021-03-02 | Novartis Ag | Derivados de 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7h-pirrolo [1',2':4,5]pirazino[1,2-b]piridazina-3,5-diona y compuestos relacionados como inhibidores de la replicacion del ortomixovirus para el tratamiento de la influenza |
| WO2020184399A1 (ja) * | 2019-03-08 | 2020-09-17 | 塩野義製薬株式会社 | 抗菌用医薬組成物 |
| CN114401970A (zh) * | 2019-09-06 | 2022-04-26 | 纳布里瓦治疗有限责任公司 | 铁载体头孢菌素缀合物及其用途 |
| AU2021210472A1 (en) * | 2020-01-22 | 2022-07-21 | Jiangsu Hengrui Medicine Co., Ltd. | Cephalosporin antibacterial compound and pharmaceutical application thereof |
| TW202220663A (zh) | 2020-07-28 | 2022-06-01 | 日商鹽野義製藥股份有限公司 | 含有具有鄰苯二酚基之頭孢菌素類的凍結乾燥製劑及其製造方法 |
| US20240132518A1 (en) * | 2021-01-12 | 2024-04-25 | Shanghai Senhui Medicine Co., Ltd. | Cephalosporin antibacterial compound and preparation method therefor |
| CN113698365A (zh) * | 2021-08-30 | 2021-11-26 | 成都大学 | 一种头孢地尔侧链的制备方法 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL47168A (en) | 1974-05-09 | 1979-07-25 | Toyama Chemical Co Ltd | Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same |
| JPS57118588A (en) | 1981-11-26 | 1982-07-23 | Toyama Chem Co Ltd | Novel cephalosporin |
| DE3207840A1 (de) | 1982-03-04 | 1983-09-15 | Hoechst Ag, 6230 Frankfurt | "cephalosporinderivate und verfahren zu ihrer herstellung" |
| US4670431A (en) | 1983-01-21 | 1987-06-02 | Beecham Group P.L.C. | Beta-lactam antibacterial agents |
| NO165842C (no) | 1984-04-23 | 1991-04-17 | Takeda Chemical Industries Ltd | Analogifremgangsmaate for fremstilling av terapeutisk aktive cefem-forbindelser. |
| EP0168177A3 (en) | 1984-06-28 | 1987-04-01 | Pfizer Limited | Cephalosporin antibiotics |
| DE3688477T2 (de) | 1985-03-01 | 1993-09-16 | Takeda Chemical Industries Ltd | Antibakterielle verbindungen, ihre herstellung und verwendung. |
| JPH068300B2 (ja) * | 1985-08-02 | 1994-02-02 | 萬有製薬株式会社 | 新規セフアロスポリン誘導体 |
| EP0211656A3 (en) | 1985-08-10 | 1988-03-09 | Beecham Group Plc | Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them |
| EP0214600B1 (en) * | 1985-09-03 | 1992-12-02 | Otsuka Kagaku Kabushiki Kaisha | Cephalosporin derivatives |
| JPH07107069B2 (ja) * | 1985-09-03 | 1995-11-15 | 大塚化学株式会社 | セフアロスポリン化合物の新規誘導体、その製造法及び該誘導体を含有する医薬組成物 |
| JPS62158291A (ja) | 1986-01-07 | 1987-07-14 | Sagami Chem Res Center | セフアロスポリン誘導体 |
| DE3750411T2 (de) * | 1986-04-14 | 1995-03-16 | Banyu Pharma Co Ltd | Cephalosporinderivate, Verfahren zu ihrer Herstellung und antibakterielle Präparate. |
| ATE92927T1 (de) * | 1986-04-14 | 1993-08-15 | Banyu Pharma Co Ltd | 1-carboxy-1-vinyloxyiminoaminothiazolcephalosporin-derivate und deren herstellung. |
| IE61679B1 (en) | 1987-08-10 | 1994-11-16 | Fujisawa Pharmaceutical Co | Water-soluble antibiotic composition and water-soluble salts of new cephem compounds |
| GB8719875D0 (en) | 1987-08-22 | 1987-09-30 | Beecham Group Plc | Compounds |
| JPH0228185A (ja) | 1988-04-14 | 1990-01-30 | Tanabe Seiyaku Co Ltd | セファロスポリン化合物及びその合成中間体 |
| GB8811055D0 (en) | 1988-05-10 | 1988-06-15 | Ici Plc | Antibiotic compounds |
| US5149803A (en) * | 1988-05-10 | 1992-09-22 | Imperial Chemical Industries Plc | Intermediates for cephalosporin compounds |
| PH25965A (en) | 1988-06-06 | 1992-01-13 | Fujisawa Pharmaceutical Co | New cephem compounds which have antimicrobial activities |
| US5244890A (en) | 1988-06-06 | 1993-09-14 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
| GB8813945D0 (en) | 1988-06-13 | 1988-07-20 | Fujisawa Pharmaceutical Co | New cephem compounds & process for preparation thereof |
| GB8817653D0 (en) * | 1988-07-25 | 1988-09-01 | Fujisawa Pharmaceutical Co | New cephem compounds & processes for preparation thereof |
| CA2005787A1 (en) | 1988-12-29 | 1990-06-29 | Masao Wada | Cephalosporin compounds |
| JPH02275886A (ja) | 1988-12-29 | 1990-11-09 | Tanabe Seiyaku Co Ltd | セファロスポリン化合物及びその製法 |
| US5143910A (en) | 1989-09-07 | 1992-09-01 | Shionogi & Co., Ltd. | Piperaziniocephalosporins |
| GB9005246D0 (en) | 1990-03-08 | 1990-05-02 | Fujisawa Pharmaceutical Co | New cephem compounds and processes for preparation thereof |
| US5095012A (en) | 1990-08-23 | 1992-03-10 | Bristol-Myers Squibb Company | Antibiotic c-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof |
| US5234920A (en) | 1990-08-23 | 1993-08-10 | Bristol-Myers Squibb Company | Antibiotic C-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof |
| US5126336A (en) | 1990-08-23 | 1992-06-30 | Bristol-Myers Squibb Company | Antibiotic c-3 catechol-substituted cephalosporin compounds, compositions and method of use thereof |
| US5194433A (en) * | 1990-11-13 | 1993-03-16 | Bristol-Myers Squibb Company | Antibiotic c-3 catechol-substituted cephalosporin compounds, compositions and method of use thereof |
| GB9111406D0 (en) | 1991-05-28 | 1991-07-17 | Fujisawa Pharmaceutical Co | New cephem compounds and processes for preparation thereof |
| GB9118672D0 (en) | 1991-08-30 | 1991-10-16 | Fujisawa Pharmaceutical Co | New cephem compounds and processes for preparation thereof |
| EP0628562A1 (fr) | 1993-06-10 | 1994-12-14 | Roussel Uclaf | Céphalosporines comportant en position 7 un radical oxymino substitué, leurs intermédiaires, leurs procédé de préparation et leur application comme médicaments |
| AU1694099A (en) | 1997-12-26 | 1999-07-19 | Cheil Jedang Corporation | Cephem derivatives and a method for producing the compounds and an antibacterialcomposition containing the compounds |
| KR20040016844A (ko) | 2001-03-27 | 2004-02-25 | 액테리온 파마슈티칼 리미티드 | 유로텐신 ⅱ 수용체 길항제인1,2,3,4-테트라하이드로이소퀴놀린 유도체 |
| JP2003078440A (ja) | 2001-08-30 | 2003-03-14 | Kyocera Corp | 高周波スイッチ回路 |
| TW200305422A (en) | 2002-03-18 | 2003-11-01 | Shionogi & Co | Broad spectrum cefem compounds |
| US6713625B2 (en) | 2002-05-23 | 2004-03-30 | Orchid Chemicals & Pharmaceuticals Ltd. | Process for the preparation of cefditoren using the thioester of thiazolylacetic acid |
| JP4892926B2 (ja) | 2005-10-25 | 2012-03-07 | 宇部興産株式会社 | スルホン化芳香族ブロック共重合体の製造方法 |
| JP3928086B2 (ja) | 2005-03-29 | 2007-06-13 | 塩野義製薬株式会社 | ３−プロペニルセフェム誘導体 |
| JP4557859B2 (ja) | 2005-09-29 | 2010-10-06 | 富士通株式会社 | 周波数分割多重送受信装置及び送受信方法 |
| WO2007096740A2 (en) | 2006-02-20 | 2007-08-30 | Orchid Research Laboratories Limited | Novel cephalosporins |
| JP2009530228A (ja) * | 2006-03-16 | 2009-08-27 | アステラス製薬株式会社 | セフェム化合物および抗菌薬としての利用 |
| AU2009310959B2 (en) | 2008-10-31 | 2015-05-07 | Shionogi & Co., Ltd. | Cephalosporin having catechol group |
| US8883773B2 (en) | 2010-04-05 | 2014-11-11 | Shionogi & Co., Ltd. | Cephem compound having pseudo-catechol group |
| MX2012011521A (es) | 2010-04-05 | 2013-03-08 | Shionogi & Co | Compuestos cefem que tienen un grupo catecol. |
| WO2011136268A1 (ja) | 2010-04-28 | 2011-11-03 | 塩野義製薬株式会社 | 新規なセフェム誘導体 |
-
2009
- 2009-10-27 AU AU2009310959A patent/AU2009310959B2/en active Active
- 2009-10-27 US US13/063,878 patent/US9238657B2/en active Active
- 2009-10-27 LT LTEP15175084.1T patent/LT2960244T/lt unknown
- 2009-10-27 PE PE2011000941A patent/PE20120010A1/es active IP Right Grant
- 2009-10-27 CN CN200980143827.5A patent/CN102203100B/zh active Active
- 2009-10-27 KR KR1020117012300A patent/KR101655961B1/ko active IP Right Grant
- 2009-10-27 ES ES15175084.1T patent/ES2602969T3/es active Active
- 2009-10-27 HU HUE15175084A patent/HUE031802T2/en unknown
- 2009-10-27 MY MYPI2011001201A patent/MY155655A/en unknown
- 2009-10-27 PL PL15175084T patent/PL2960244T3/pl unknown
- 2009-10-27 SI SI200931549A patent/SI2960244T1/sl unknown
- 2009-10-27 EP EP09823578.1A patent/EP2341053B1/en active Active
- 2009-10-27 PT PT151750841T patent/PT2960244T/pt unknown
- 2009-10-27 JP JP2010535799A patent/JP5498393B2/ja active Active
- 2009-10-27 CA CA2736953A patent/CA2736953C/en active Active
- 2009-10-27 DK DK15175084.1T patent/DK2960244T3/en active
- 2009-10-27 NZ NZ591728A patent/NZ591728A/xx unknown
- 2009-10-27 EA EA201170632A patent/EA019520B1/ru unknown
- 2009-10-27 ME MEP-2016-246A patent/ME02666B/me unknown
- 2009-10-27 EP EP15175084.1A patent/EP2960244B1/en active Active
- 2009-10-27 WO PCT/JP2009/068400 patent/WO2010050468A1/ja active Application Filing
- 2009-10-27 MX MX2011004636A patent/MX2011004636A/es active IP Right Grant
- 2009-10-27 ES ES09823578.1T patent/ES2564836T3/es active Active
- 2009-10-27 RS RS20160919A patent/RS55365B1/sr unknown
- 2009-10-27 UA UAA201106802A patent/UA105190C2/ru unknown
- 2009-10-27 BR BRPI0921701A patent/BRPI0921701B8/pt active IP Right Grant
- 2009-10-30 TW TW098136792A patent/TWI535727B/zh active
-
2011
- 2011-03-14 IL IL211720A patent/IL211720A/en active IP Right Grant
- 2011-03-17 ZA ZA2011/02024A patent/ZA201102024B/en unknown
- 2011-03-18 CR CR20110144A patent/CR20110144A/es unknown
- 2011-04-27 CL CL2011000939A patent/CL2011000939A1/es unknown
- 2011-04-29 MA MA33798A patent/MA32731B1/fr unknown
- 2011-05-02 CO CO11053320A patent/CO6331443A2/es active IP Right Grant
-
2013
- 2013-12-16 JP JP2013259499A patent/JP2014065732A/ja active Pending
-
2016
- 2016-10-27 HR HRP20161408TT patent/HRP20161408T1/hr unknown
- 2016-11-07 SM SM201600397T patent/SMT201600397B/it unknown
- 2016-11-16 CY CY20161101180T patent/CY1118536T1/el unknown
-
2020
- 2020-10-13 NL NL301067C patent/NL301067I2/nl unknown
- 2020-10-15 FR FR20C1050C patent/FR20C1050I2/fr active Active
- 2020-10-15 LT LTPA2020530C patent/LTPA2020530I1/lt unknown
- 2020-10-16 CY CY2020034C patent/CY2020034I2/el unknown
- 2020-10-19 FI FIC20200039C patent/FIC20200039I1/fi unknown
- 2020-10-21 NO NO2020035C patent/NO2020035I1/no unknown
- 2020-10-21 HU HUS2000042C patent/HUS2000042I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2020035I1 (no) | cefiderokol, eventuelt på formen av et farmasøytisk akseptabelt salt eller solvat | |
| NO2019042I1 (no) | Talazoparib, eventuelt i form av et farmasøytisk aksepterbart salt | |
| NO2020037I1 (no) | alpelisib eller et farmasøytisk akseptabelt salt derav | |
| NO2020018I1 (no) | Darolutamide, optionally in the form of a pharmaceutically acceptable salt or ester thereof | |
| NO2019024I1 (no) | Brigatinib eller et farmasøytisk akseptabelt salt derav | |
| NO2019012I1 (no) | Enkorafenib eller et farmasøytisk akseptabelt salt eller solvat derav | |
| NO2017059I1 (no) | ribosiklib eller et farmasøytisk akseptabelt salt derav | |
| NO2020039I1 (no) | Ozanimod eller et farmasøytisk akseptabelt salt derav, særlig ozanimodhydroklorid | |
| NO2020034I1 (no) | Ozanimod eller et farmasøytisk akseptabelt salt derav, særlig ozanimodhydroklorid | |
| NO2019027I1 (no) | kobicistat eller et farmasøytisk akseptabelt salt derav | |
| NO2020027I1 (no) | glasdegib, eventuelt i form av et farmasøytisk akseptabelt salt, inkludert maleatsaltet | |
| FIC20240016I1 (fi) | Dolutegraviiri tai sen farmaseuttisesti hyväksyttävä suola, mukaan lukien dolutegraviirinatrium, ja lamivudiini | |
| NO2020038I1 (no) | Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt | |
| NO2021018I1 (no) | kabotegravir eller et farmasøytisk akseptabelt salt eller solvat derav | |
| NO2019010I1 (no) | Eravasyklin eller farmasøytisk akseptable salter derav | |
| NO2020006I1 (no) | upadacitinib or a pharmaceutically acceptable salt thereof | |
| NO2017057I1 (no) | pibrentasvir eller et farmasøytisk akseptabelt salt derav | |
| NO2016016I1 (no) | Lesinurad, eller et farmasøytisk akseptabelt salt derav | |
| NO2022033I1 (no) | Rimegepant or a pharmaceutically acceptable salt thereof | |
| CY2018030I2 (el) | Φαρμακοτεχνικη μορφη 514 | |
| NO2015014I1 (no) | Paritaprevir, eller et farmasøytisk akseptabelt salt eller ester derav | |
| HUS000509I2 (hu) | Abemaciklib vagy egy gyógyászatilag elfogadható sója | |
| NO2017004I1 (no) | Grazoprevir eller et farmasøytisk akseptabelt stoff derav | |
| NO2017024I1 (no) | Elosulfase alfa eller et farmasøytisk akseptabelt salt derav | |
| NO2016014I2 (no) | ceritinib eller farmasøytisk akseptable salter derav |